Published in The Lancet, results of the phase III LITESPARK-011 clinical trial point to the combination of belzutifan plus lenvatinib…
Cristina Suárez
Results from the international, randomized phase III LITESPARK-022 study show that the addition of hypoxia-inducible factor-2 alpha (HIF-2 α) inhibitor…
Coinciding with World Kidney Cancer Day, on 20 June La Colla Vella dels Xiquets de Valls organised a moving event…
The single arm phase II CALYPSO study evaluated the efficacy of MET inhibitor savolitinib combined with PD-L1 inhibitor durvalumab in…
Results from sub-study 03A of KEYMAKER-U03, an international, open-label, rolling-arm, phase I/II umbrella trial, spotlight the promise of pembrolizumab-based…
The phase 2, international, multicenter SUNNIFORECAST study, directed by Lothar Bergmann of the Medical Clinic II, University Hospital Frankfurt in…
The phase 3 open-label, randomized NIAGARA trial was designed to evaluate the benefits of adding perioperative immunotherapy durvalumab to standard…
Results of the phase III LITESPARK-005 clinical trial show that treatment with belzutifan versus everolimus significantly improves progression-free survival in…
Presented today at the ESMO Congress 2023, results of the phase III LITESPARK-005 study show that treatment with belzutifan versus…
Published in The Lancet Oncology (1) and co-authored by VHIO’s Cristina Suarez, results from the single-arm phase II KEYNOTE-B61 clinical…
